Nasdaq Warns Telomir Pharmaceuticals Over Delayed Annual Shareholder Meeting
I'm PortAI, I can summarize articles.
Telomir Pharmaceuticals Inc. has been notified by Nasdaq for failing to comply with Listing Rule 5620(a), which mandates annual shareholder meetings within twelve months of the fiscal year-end. The delay is due to the SEC's review of the company's proxy statement, originally set for December 30, 2025. Telomir must submit a compliance plan by February 23, 2026, and plans to hold the meeting promptly after SEC approval. The notice does not impact the trading or listing of its shares.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments